Leuprorelin (Leuprolide)
(Synonyms: 亮丙瑞林) 目录号 : GC31000
Leuprorelin (Leuprolide)是一种促性腺激素释放激素(GnRH)类似物 ,在垂体GnRH受体中起激动剂的作用。
Cas No.:53714-56-0
Sample solution is provided at 25 µL, 10mM.
Leuprorelin (Leuprolide) is a gonadotropin-releasing hormone (GnRH) analog that acts as an agonist at the pituitary GnRH receptor[1]. Leuprorelin is primarily used to treat various sex hormone-related diseases, including advanced prostate cancer, endometriosis, and precocious puberty[2]. Continuous administration of Leuprorelin can induce pituitary desensitization and/or receptor downregulation, thereby suppressing the levels of gonadotropins and sex hormones in the blood circulation, leading to hypogonadism[3, 4]. Leuprorelin is more stable than natural GnRH and has a stronger receptor affinity[5].
References:
[1] Casati L, Ciceri S, Maggi R, et al. Physiological and pharmacological overview of the gonadotropin releasing hormone[J]. Biochemical pharmacology, 2023, 212: 115553.
[2] Plosker G L, Brogden R N. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders[J]. Drugs, 1994, 48(6): 930-967.
[3] Wu H M, Chang H M, Leung P C K. Gonadotropin-releasing hormone analogs: Mechanisms of action and clinical applications in female reproduction[J]. Frontiers in neuroendocrinology, 2021, 60: 100876.
[4] Wuttke W, Jarry H, Feleder C, et al. The neurochemistry of the GnRH pulse generator[J]. Acta neurobiologiae experimentalis, 1996, 56(3): 707-713.
[5] Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin[J]. Clinical pharmacokinetics, 2002, 41: 485-504.
Leuprorelin (Leuprolide)是一种促性腺激素释放激素(GnRH)类似物 ,在垂体GnRH受体中起激动剂的作用[1]。Leuprorelin主要用于治疗各种性激素相关疾病,包括晚期前列腺癌、子宫内膜异位症和性早熟[2]。Leuprorelin持续给药可诱导垂体脱敏和/或受体下调,从而抑制血液循环中的促性腺激素和性激素水平,导致性腺功能低下[3, 4]。Leuprorelin比天然GnRH更稳定,具有更强的受体亲和力[5]。
Cas No. | 53714-56-0 | SDF | |
别名 | 亮丙瑞林 | ||
Canonical SMILES | {pGlu}-His-Trp-Ser-Tyr-{d-Leu}-Leu-Arg-Pro-NHEt | ||
分子式 | C59H84N16O12 | 分子量 | 1209.4 |
溶解度 | >20.6 mg/mL in H2O; >22 mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 0.8269 mL | 4.1343 mL | 8.2686 mL |
5 mM | 0.1654 mL | 0.8269 mL | 1.6537 mL |
10 mM | 0.0827 mL | 0.4134 mL | 0.8269 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet